Effects of psychedelic, DOI, on nucleus accumbens dopamine signaling to predictable rewards and cues in rats
David Martin, Angel M. Delgado, Donna J. Calu
Neuropsychopharmacology July 6, 2024 DOI: 10.1038/s41386-024-01912-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | DOI |
| Dose | 0.0-1.2 mg/kg, i.p. |
| Keywords | Nucleus accumbens Dopamine |
| Citations | 3 |
| Key findings | DOI increases dopamine signals to rewards and proximal reward cues but not to distal cues, independent of reward value, indicating enhanced prediction error signaling. |
Abstract
Psychedelics produce lasting therapeutic responses in neuropsychiatric diseases suggesting they may disrupt entrenched associations and catalyze learning. Here, we examine psychedelic 5-HT2A/2C agonist, DOI, effects on dopamine signaling in the nucleus accumbens (NAc) core, a region extensively linked to reward learning, motivation, and drug-seeking. We measure phasic dopamine transients following acute DOI administration in rats during well learned Pavlovian tasks in which sequential cues predict rewards. We find that DOI (0.0-1.2 mg/kg, i.p.) increases dopamine signals, photometrically measured using GRABDA optical sensor, to rewards and proximal reward cues, but not to the distal cues that predict these events. We determine that the elevated dopamine produced by DOI to reward cues occurs independently of DOI-induced changes in reward value. The increased dopamine associated with predictable reward cues and rewards supports DOI-induced increases in prediction error signaling. These findings lay a foundation for developing psychedelic strategies aimed at engaging error-driven learning mechanisms to disrupt entrenched associations or produce new associations.
Citations in the library
Cited by 4
- Learning as the unifying mechanism of psychedelic action Journal of Psychopharmacology December 26, 2025
- Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review Schizophrenia Research March 13, 2026
- Psilocybin collapses visual change detection and drives cortical dynamics toward a state of surprise bioRxiv (Cold Spring Harbor Laboratory) August 25, 2026
- Psychedelics and Reward Processing: Before and After the 1970 Controlled Substances Act Psychedelic Medicine July 24, 2026
Cites 28
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 23 more in the library